A Phase 2 interventional study of CDX-3379 and cetuximab in Advanced Head and Neck Squamous Cell Carcinoma, sponsored by Celldex Therapeutics. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-03.
Sponsored by Celldex Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cetuximab in Mouth Neoplasms — 3 open to participants now, 4 under way, 2 of them phase 3. Cetuximab · Mouth Neoplasms.
Among the 10 studies testing cetuximab in Mouth Neoplasms, this one is the 9th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 2, and was the 7th registered.
447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.
Browse Mouth Neoplasms studies →3 of the 10 studies testing cetuximab in Mouth Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 8 · Phase 3 2
First in 2007; this study’s year is marked.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 60 across 313 interventional studies indexed under Mouth Neoplasms.
Median enrollment 44 across the 10 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 8 most frequent:
Celldex Therapeutics is the lead sponsor of 45 studies on the registry; 3 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 1 (7%) have results posted.
Celldex Therapeutics has 2 studies filed under Mouth Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing cetuximab in Mouth Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448026M.D. Anderson Cancer CenterCemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma | 2027-05-15 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing cetuximab in Mouth Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to determine the clinical benefit (how well the drug works), safety and tolerability of combining CDX-3379 and cetuximab. The study will enroll patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.
CDX-3379 is a fully human monoclonal antibody that binds to a molecule called human epidermal growth factor receptor 3 (HER3 or ErbB3) found on certain cells and may act to promote anti-tumor effects.
Cetuximab is a human monoclonal antibody that blocks EGFR, a protein receptor that regulates cell growth.
This study will evaluate the safety, tolerability and efficacy of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma who have previously received cetuximab and progressed.
Eligible patients that enroll in the study will be given the dose of 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
Up to 45 patients will be enrolled. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the treatment phase of the study, eligible patients will receive assigned treatments in 3 week cycles until progression.
Drug: CDX-3379 and cetuximab
Objective Response Rate
The percentage of patients who achieve a complete response or partial response per Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1), Complete Response (CR) = disappearance of all target lesions and non-target lesions, Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions with no progression in non-target lesions and no new lesions.
Time frame: The proportion of evaluable patients who achieve a best overall response of complete or partial response according to RECIST 1.1 assessed up to 24 months.
Clinical Benefit Response (CBR)
The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks
Time frame: Every 8 weeks, starting with first dose until disease progression, assessed up to approximately 2 years
Duration of Response (DOR)
The interval from which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented
Time frame: First occurrence of a documented objective response to disease progression or death (up to approximately 2 years)
Progression-free Survival (PFS)
The time from start of study drug to time of progression or death, whichever occurs first
Time frame: From first dose to the first occurrence of disease progression or death due to any cause (up to approximately 2 years)
Overall Survival (OS)
The time from start of study drug to death
Time frame: The time from start of study drug to death from any cause (up to approximately 2 years)
Incidence of Adverse Events [Safety and Tolerability]
Safety and tolerability of CDX-3379 in combination with cetuximab as determined by incidence and severity of adverse events. Percentage of patients reporting one or more adverse events.
Time frame: Following at least one dose of study treatment through 30 days after last dose of CDX-3379.
Tumor DNA Biomarkers.
Tumor DNA biomarkers will be evaluated and assessed for correlation with clinical efficacy. Objective response rate for subset of patients with FAT1 positive tumor is reported.
Time frame: Tumor tissue is obtained during screening window via single biopsy procedure.
| Milestone | CDX-3379 and Cetuximab |
|---|---|
| Started | 30 |
| Completed | 30 |
| Not completed | 0 |
The percentage of patients who achieve a complete response or partial response per Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST version 1.1), Complete Response (CR) = disappearance of all target lesions and non-target lesions, Partial Response (PR), \>= 30% decrease in the sum of the longest diameter of target lesions with no progression in non-target lesions and no new lesions.
| percentage of participants | CDX-3379 and Cetuximab |
|---|---|
| Objective Response Rate | 7 (0.8 to 22.1) |
The percentage of patients who achieve best response of confirmed CR or PR, or stable disease (SD) for at least 12 weeks
| percentage of participants | CDX-3379 and Cetuximab |
|---|---|
| Clinical Benefit Response (CBR) | 40 (22.7 to 59.4) |
The interval from which measurement criteria are first met for Complete Response (CR) or Partial Response (PR) until the first date that progressive disease is objectively documented
| months | CDX-3379 and Cetuximab |
|---|---|
| Duration of Response (DOR) | NA |
The time from start of study drug to time of progression or death, whichever occurs first
| months | CDX-3379 and Cetuximab |
|---|---|
| Progression-free Survival (PFS) | 2.2 (1.3 to 3.6) |
The time from start of study drug to death
| months | CDX-3379 and Cetuximab |
|---|---|
| Overall Survival (OS) | 6.6 (2.7 to 7.5) |
Safety and tolerability of CDX-3379 in combination with cetuximab as determined by incidence and severity of adverse events. Percentage of patients reporting one or more adverse events.
| Participants | CDX-3379 and Cetuximab |
|---|---|
| Incidence of Adverse Events [Safety and Tolerability] | 30 |
Tumor DNA biomarkers will be evaluated and assessed for correlation with clinical efficacy. Objective response rate for subset of patients with FAT1 positive tumor is reported.
| Participants | CDX-3379 and Cetuximab |
|---|---|
| Tumor DNA Biomarkers. | 1 |
Collected over Adverse events were collected from initiation of treatment until 30 days after discontinuing treatment or initiation of new anti-cancer medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CDX-3379 and Cetuximab | 26/30 (86.7%) | 13/30 (43.3%) | 30/30 (100%) |
| Event | CDX-3379 and Cetuximab |
|---|---|
| PneumoniaInfections and infestations | 3/30 |
| DiarrhoeaGastrointestinal disorders | 2/30 |
| PyrexiaGeneral disorders | 2/30 |
| Lung abscessInfections and infestations | 1/30 |
| InfectionInfections and infestations | 1/30 |
| Urinary tract infectionInfections and infestations | 1/30 |
| Small intestinal haemorrhageGastrointestinal disorders | 1/30 |
| Mucosal inflammationGeneral disorders | 1/30 |
| Non-cardiac chest painGeneral disorders | 1/30 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/30 |
| Event | CDX-3379 and Cetuximab |
|---|---|
| DiarrhoeaGastrointestinal disorders | 24/30 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 17/30 |
| HypomagnesaemiaMetabolism and nutrition disorders | 16/30 |
| HypokalaemiaMetabolism and nutrition disorders | 14/30 |
| FatigueGeneral disorders | 11/30 |
| NauseaGastrointestinal disorders | 10/30 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 10/30 |
| Weight decreasedInvestigations | 10/30 |
| HypophosphataemiaMetabolism and nutrition disorders | 9/30 |
| DysphagiaGastrointestinal disorders | 8/30 |
| Age, Continuous(years) | CDX-3379 and Cetuximab |
|---|---|
| Mean | 62 (46 to 79) |
| Sex: Female, Male(Participants) | CDX-3379 and Cetuximab |
|---|---|
| Female | 4 |
| Male | 26 |
| Ethnicity (NIH/OMB)(Participants) | CDX-3379 and Cetuximab |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 26 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | CDX-3379 and Cetuximab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 25 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | CDX-3379 and Cetuximab |
|---|---|
| United States | 30 |
| Site of Primary Tumor(Participants) | CDX-3379 and Cetuximab |
|---|---|
| Pharynx/Oropharynx | 12 |
| Oral Cavity | 11 |
| Larynx | 4 |
| Other | 3 |
| Duration of Metastatic Disease(years) | CDX-3379 and Cetuximab |
|---|---|
| Mean | 2.2 (1 to 17) |
| ECOG Performance Status(Participants) | CDX-3379 and Cetuximab |
|---|---|
| ECOG 0 | 4 |
| ECOG 1 | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2018 to primary completion in Sep 2020, 29 months.
Results were first posted in Apr 2023, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: CDX-3379 · Cetuximab